華大基因(300676.SZ)子公司地中海貧血基因檢測產品獲CE准入資質
格隆匯1月27日丨華大基因(300676.SZ)公佈,公司全資子公司華大生物科技(武漢)有限公司(以下簡稱武漢生物科技)研製的地中海貧血基因檢測試劑盒(聯合探針錨定聚合測序法)於近日獲得歐盟CE准入資質。
地中海貧血難治但可防,通過婚前、孕前和產前階段對育齡人羣進行地中海貧血篩查、診斷和干預,可以有效降低中、重型地中海貧血患兒出生。公司是高通量測序技術檢測地中海貧血的引領者,所開發的地中海貧血基因檢測新技術具有準確率高、檢測全面、高通量和低成本等優勢,將為全球的地中海貧血和其他血紅蛋白病(如鐮狀細胞性貧血)的防控提供了一種新的技術方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.